Literature DB >> 25432733

Movement disorders in systemic diseases.

Werner Poewe1, Atbin Djamshidian-Tehrani2.   

Abstract

Movement disorders, classically involving dysfunction of the basal ganglia commonly occur in neurodegenerative and structural brain disorders. At times, however, movement disorders can be the initial manifestation of a systemic disease. In this article we discuss the most common movement disorders which may present in infectious, autoimmune, paraneoplastic, metabolic and endocrine diseases. Management often has to be multidisciplinary involving primary care physicians, neurologists, allied health professionals including nurses, occupational therapists and less frequently neurosurgeons. Recognizing and treating the underlying systemic disease is important in order to improve the neurological symptoms.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autoimmune disorders; Basal ganglia; Endocrine disorders; Intoxications; Metabolic disorders; Movement disorders; Paraneoplastic disorders; Systemic disease

Mesh:

Year:  2015        PMID: 25432733     DOI: 10.1016/j.ncl.2014.09.015

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  4 in total

Review 1.  Movement Disorders in Metabolic Disorders.

Authors:  José Luiz Pedroso; Orlando G Barsottini; Alberto J Espay
Journal:  Curr Neurol Neurosci Rep       Date:  2019-02-09       Impact factor: 5.081

2.  Chorea, Pruritus and Polycythemia: Looking for Clues.

Authors:  Vânia Rodrigues; Carolina Lopes; Adilson Marcolino; Madalena Pinto
Journal:  Eur J Case Rep Intern Med       Date:  2019-02-06

3.  Case report: Albendazole associated psychosis.

Authors:  Bennett Doughty; L Nathan Tumey; Karen Williams
Journal:  Ment Health Clin       Date:  2019-11-27

4.  Metformin Prevents Dopaminergic Neuron Death in MPTP/P-Induced Mouse Model of Parkinson's Disease via Autophagy and Mitochondrial ROS Clearance.

Authors:  Ming Lu; Cunjin Su; Chen Qiao; Yaqi Bian; Jianhua Ding; Gang Hu
Journal:  Int J Neuropsychopharmacol       Date:  2016-09-21       Impact factor: 5.176

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.